Fri, August 19, 2022
Thu, August 18, 2022
Wed, August 17, 2022
Tue, August 16, 2022
Mon, August 15, 2022
Fri, August 12, 2022

Derek Archila Maintained (BPMC) at Sell with Increased Target to $41 on, Aug 17th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-increased-target-to-41-on-aug-17th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Derek Archila of Wells Fargo, Maintained "Blueprint Medicines Corporation" (BPMC) at Sell with Increased Target from $40 to $41 on, Aug 17th, 2022.

Derek has made no other calls on BPMC in the last 4 months.



There are 8 other peers that have a rating on BPMC. Out of the 8 peers that are also analyzing BPMC, 3 agree with Derek's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Andrew Berens of "SVB Leerink" Maintained at Hold with Increased Target to $65 on, Wednesday, August 3rd, 2022
  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $65 on, Tuesday, June 14th, 2022
  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022


These are the ratings of the 5 analyists that currently disagree with Derek


  • Dane Leone of "Raymond James" Maintained at Strong Buy with Decreased Target to $115 on, Wednesday, August 3rd, 2022
  • Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $143 on, Wednesday, August 3rd, 2022
  • Matthew Biegler of "Oppenheimer" Initiated at Buy and Held Target at $80 on, Friday, July 8th, 2022
  • David Lebowitz of "Citigroup" Downgraded from Hold to Strong Sell and Decreased Target to $41 on, Friday, June 10th, 2022
  • Eun Yang of "Jefferies" Upgraded from Hold to Strong Buy and Decreased Target to $78 on, Wednesday, June 1st, 2022

Publication Contributing Sources